Regeneron

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Regeneron and other ETFs, options, and stocks.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

13,450

Employees13,450

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

13,450

Employees13,450

REGN Key Statistics

Market cap

97.96B

Market cap97.96B

Price-Earnings ratio

25.71

Price-Earnings ratio25.71

Dividend yield

—

Dividend yield—

Average volume

486.41K

Average volume486.41K

High today

$920.73

High today$920.73

Low today

$891.67

Low today$891.67

Open price

$912.25

Open price$912.25

Volume

164.14K

Volume164.14K

52 Week high

$998.33

52 Week high$998.33

52 Week low

$684.81

52 Week low$684.81

REGN News

Yahoo Finance 2h

Regeneron Pharmaceuticals Insiders Sell US$26m Of Stock, Possibly Signalling Caution - Yahoo Finance

Over the past year, many Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders sold a significant stake in the company which may have piqued investors' interes...

Benzinga 1d

Market Analysis: Regeneron Pharmaceuticals And Competitors In Biotechnology Industry - Regeneron Pharmace - Benzinga

Loading... Loading... In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess...

Seeking Alpha 3d

Regeneron to 'vigorously defend' against DOJ on Eylea pricing complaint - Seeking Alpha

Regeneron (NASDAQ:REGN) announced that the company will "vigorously defend" itself in court after the U.S. Department of Justice filed a lawsuit on allegations...

Analyst ratings

69%

of 29 ratings

Buy

69%

Hold

24.1%

Sell

6.9%

More REGN News

Reuters 4d

UPDATE 1-Regeneron to defend against DOJ complaint on drug-price manipulation

(Adds details from the statement in paragraph 2 and adds background paragraph 3 onwards) April 15 (Reuters) - Regeneron Pharmaceuticals said on Monday it seeks...

Yahoo Finance 4d

Roche reports survival data for new dual-acting lymphoma drug - Yahoo Finance

Dive Brief: Roche’s new dual-acting blood cancer drug Columvi combined with chemotherapy helped people with a type of lymphoma live longer than people given Ri...

Yahoo Finance 4d

Regeneron commits $500M to new venture capital fund - Yahoo Finance

Dive Brief: Regeneron Pharmaceuticals is getting into biotechnology investing, committing $500 million over the next five years to an independent venture capit...

Yahoo Finance 7d

Regeneron Accused of Fraudulent Practices Related to Eylea - Yahoo Finance

Shares of Regeneron Pharmaceuticals REGN were down 1.70% on Apr 11, following a complaint filed by the U.S. Department of Justice against the company, alleging...

TipRanks 7d

RBC sees buying opportunity following Regeneron's 'overdone DOJ downside' - TipRanks.com - TipRanks

RBC Capital notes that the Department of Justice has filed a complaint against Regeneron, accusing the company of fraudulently inflating Medicare reimbursement...